AbbVie Inc annual ebitda for fiscal 2025 was $17.6 billion, an increase of 18.2% from $14.9 billion in fiscal 2024. Trailing-twelve-month ebitda is $16.9 billion. All figures are reported results from public filings — no estimates or projections.
| EBITDA (annual) | TTM | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EBITDA | $16.9B | $17.6B | $14.9B | $17.2B | $24.2B | $23.9B | $12.3B | $12.2B | $8.3B | $10.4B | $10.1B | $8.2B | $3.6B | $6.5B | $7.0B | $4.9B | $6.0B | $5.8B |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| EBITDA (quarterly) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|
| EBITDA | $3.7B | $5.4B | $3.5B | $4.3B | $4.4B | $535M | $4.9B | $5.0B |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More ABBV metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · Free Cash Flow · Shares Outstanding
All ABBV financial statements → Interactive ABBV charts →
About TickerBase · Data methodology & sources